Coagulopathy as a therapeutic target for TRALI: Rationale and possible sites of action

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3267-3272

  Tuinman, Pieter R ^a   Schultz, Marcus J ^a   Juffermans, Nicole P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acetylsalicylic acid; ALI; Coagulation; Fibrinolysis; Platelets; Therapy; Trali

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN; CD31 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FIBRIN; GLYCOPROTEIN IB; GLYCOPROTEIN IIIA; HEPARIN; INTERLEUKIN 1; INTERLEUKIN 6; PADGEM PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; THROMBOSPONDIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; APACHE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; DRUG MEGADOSE; FIBRINOLYSIS; HUMAN; LOW DRUG DOSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 84861150809     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023267     Document Type: Review

References (97)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1334-9.
2. Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol 2009; 147(4): 431-43.
3. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34(5 Suppl): S124-31.
4. Thakur SJ, Trillo-Alvarez CA, Malinchoc MM, et al. Towards the prevention of acute lung injury: a population based cohort study protocol. BMC Emerg Med 2010; 10: 8.
5. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007; 369(9572): 1553-64.
6. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19(1): 2-31.
7. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995; 332(1): 27-37.
8. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review. Crit Care Med 2006; 34(3): 871-7.
9. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models. Curr Med Chem 2008; 15(6): 588-95.
10. Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis 1987; 135(2): 482-92.
11. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front Biosci 2009; 14: 150-8.
12. Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2009; 40(2): 123-34.
13. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119(11): 3450-61.
14. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Pre-hospitalization anti-platelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 2010.
15. Vlaar AP, Hofstra JJ, Levi M, et al. Supernatant of aged erythrocytes causes lung inflammation and coagulopathy in a two-hit in vivo syngeneic transfusion model. Anesthesiology 2010; 113(1): 92-103.
16. Vlaar AP, Hofstra JJ, Kulik W, et al. Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel in vivo transfusion model. Blood 2010; 116(8): 1360-8.
17. Hidalgo A, Chang J, Jang JE, Peired AJ, Chiang EY, Frenette PS. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009; 15(4): 384-91.
18. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med 2010; 38(3): 771-8.
19. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176(9): 886-91.
20. MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007; 27(6): 860-73.
21. Levi M, ten CH. Disseminated intravascular coagulation. N Engl J Med 1999; 341(8): 586-92.
22. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699-709.
23. Levi M, ten CH, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93(1): 114-20.
24. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101(3): 816-23.
25. Fuchs-Buder T, De MP, Ricou B, et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153(1): 163-7.
26. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161(2 Pt 1): 454-62.
27. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285(1): L20-8.
28. Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31(4 Suppl): S329-36.
29. Zapol WM, Jones R. Vascular components of ARDS. Clinical pulmonary hemodynamics and morphology. Am Rev Respir Dis 1987; 136(2): 471-4.
30. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J Trauma 1999; 47(4): 719-23.
31. Choi G, Schultz MJ, Levi M, van der Poll T, Millo JL, Garrard CS. Protein C in pneumonia. Thorax 2005; 60(8): 705-6.
32. El Solh AA, Choi G, Schultz MJ, Pineda LA, Mankowski C. Clinical and hemostatic responses to treatment in ventilatorassociated pneumonia: role of bacterial pathogens. Crit Care Med 2007; 35(2): 490-6.
33. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets? Keio J Med 2005; 54(3): 142-9.
34. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285(3): L514-21.
35. Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976; 61(5): 585-9.
36. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261(4 Pt 1): L240-8.
37. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27(8): 1687-93.
38. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21(2): 99-111.
39. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12(5): 261-73.
40. Basit A, Reutershan J, Morris MA, Solga M, Rose CE, Jr., Ley K. ICAM-1 and LFA-1 play critical roles in LPS-induced neutrophil recruitment into the alveolar space. Am J Physiol Lung Cell Mol Physiol 2006; 291(2): L200-7.
41. Kiefmann R, Heckel K, Schenkat S, Dorger M, Wesierska-Gadek J, Goetz AE. Platelet-endothelial cell interaction in pulmonary microcirculation: the role of PARS. Thromb Haemost 2004; 91(4): 761-70.
42. Schulz C, Schafer A, Stolla M, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116(7): 764-73.
43. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116(12): 3211-9.
44. Barrett J, Dawidson I, Dhurandhar HN, Miller E, Litwin MS. Pulmonary microembolism associated with massive transfusion: II. The basic pathophysiology of its pulmonary effects. Ann Surg 1975; 182(1): 56-61.
45. QUICK AJ, GEORGATSOS JG, HUSSEY CV. The clotting activity of human erythrocytes: theoretical and clinical implications. Am J Med Sci 1954; 228(2): 207-13.
46. Tuinman PR, Vlaar AP, Cornet AD, et al. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care 2011; 15(1): R59.
47. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35(8): 1821-8.
48. Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006; 84(5): 398-405.
49. Song Y, Lynch SV, Flanagan J, et al. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007; 106(2): 252-61.
50. Kiefmann R, Heckel K, Schenkat S, Dorger M, Goetz AE. Role of p-selectin in platelet sequestration in pulmonary capillaries during endotoxemia. J Vasc Res 2006; 43(5): 473-81.
51. Galley HF, El Sakka NE, Webster NR, Lowes DA, Cuthbertson BH. Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008; 100(6): 815-9.
52. Abraham E. Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005; 2(3): 243-7.
53. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104(13): 3878-85.
54. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109(8): 3161-72.
55. Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35(5): 1362-8.
56. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33(5): 952-61.
57. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178(6): 618-23.
58. Guerin C, Richard JC. On the randomized trial of activated protein C in acute lung injury. Am J Respir Crit Care Med 2009; 179(2): 172-3.
59. Rubenfeld GD, Abraham E. When is a negative phase II trial truly negative? Am J Respir Crit Care Med 2008; 178(6): 554-5.
60. Hoffmann JN, Fertmann JM, Jauch KW. Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C. Curr Opin Crit Care 2006; 12(5): 426-30.
61. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30(5 Suppl): S325-31.
62. Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36(1): 204-10.
63. Salvatierra A, Guerrero R, Rodriguez M, et al. Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog. Circulation 2001; 104(24): 2975-80.
64. Harada N, Okajima K, Uchiba M, Kushimoto S, Isobe H. Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb Haemost 2004; 92(3): 550-8.
65. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebocontrolled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24(7): 663-72.
66. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286(15): 1869-78.
67. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006; 133(1): 62-7.
68. Cox CS, Jr., Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993; 176(4): 339-49.
69. Cadroy Y, Gaspin D, Dupouy D, Lormeau JC, Boneu B, Sie P. Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemost 1996; 75(1): 190-5.
70. Gori AM, Pepe G, Attanasio M, et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81(4): 589-93.
71. Pepe G, Giusti B, Attanasio M, et al. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemost 1997; 23(2): 135-41.
72. Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 1990; 1(2): 133-8.
73. Dixon B, Opeskin K, Stamaratis G, et al. Pre-operative heparin reduces pulmonary microvascular fibrin deposition following cardiac surgery. Thromb Res 2011; 127(1): e27-e30.
74. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010; 14(5): R180.
75. van den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, antiinflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9(1): 122-32.
76. Sigurdsson GH, Vallgren S, Christenson JT. Influence of aspirin and steroids on acute lung injury after i.v. Injection of a sclerosing agent. Acta Chir Scand 1989; 155(3): 163-70.
77. Sigurdsson GH, Youssef HA, Owunnwanne A. Effects of two different inhibitors of the arachidonic acid metabolism on platelet sequestration in endotoxic shock. Res Exp Med (Berl) 1994; 194(5): 287-95.
78. Chelucci GL, Boncinelli S, Marsili M, et al. Aspirin effect on early and late changes in acute lung injury in sheep. Intensive Care Med 1993; 19(1): 13-21.
79. Chen ZT, Li SL, Cai EQ, Wu WL, Jin JS, Zhu B. LPS induces pulmonary intravascular macrophages producing inflammatory mediators via activating NF-kappaB. J Cell Biochem 2003; 89(6): 1206-14.
80. Wahn H, Hammerschmidt S. Inhibition of PMNand HOC1-induced vascular injury in isolated rabbit lungs by acetylsalicylic acid: a possible link between neutrophil-derived oxidative stress and eicosanoid metabolism? Biochim Biophys Acta 1998; 1408(1): 55-66.
81. Wahn H, Hammerschmidt S. Influence of cyclooxygenase and lipoxygenase inhibitors on oxidative stress-induced lung injury. Crit Care Med 2001; 29(4): 802-7.
82. Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 2009; 37(6): 1874-80.
83. Eid A, Wiedermann CJ, Kinasewitz GT. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. Anesth Analg 2008; 107(5): 1633-8.
84. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11): 2081-9.
85. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010; 14(5): 445.
86. Heslet L, Andersen JS, Sengelov H, Dahlback B, Dalsgaard-Nielsen J. Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome. Biologics 2007; 1(4): 465-72.
87. Hofstra JJ, Vlaar AP, Cornet AD, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010; 23(2): 105-11.
88. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009; 30(2): 249-56.
89. Vlaar AP, Schultz MJ, Juffermans NP. Transfusion-related acute lung injury: a change of perspective. Neth J Med 2009; 67(10): 320-6.
90. Iwata H, Kaibara M. Activation of factor IX by erythrocyte membranes causes intrinsic coagulation. Blood Coagul Fibrinolysis 2002; 13(6): 489-96.
91. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116(6): 1615-23.
92. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69(6): 1366-72.
93. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353(22): 2373-2383.
94. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23(4): 349-56.
95. Adawi A, Zhang Y, Baggs R, Finkelstein J, Phipps RP. Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. Am J Pathol 1998; 152(3): 651-7.
96. Fulkerson WJ, MacIntyre N, Stamler J, Crapo JD. Pathogenesis and treatment of the adult respiratory distress syndrome. Arch Intern Med 1996; 156(1): 29-38.
97. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 2005; 174(8): 5033-9.